Press coverage about VIVUS (NASDAQ:VVUS) has trended somewhat positive on Monday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. VIVUS earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 44.0680562195509 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

A number of research firms recently weighed in on VVUS. Zacks Investment Research raised shares of VIVUS from a “hold” rating to a “buy” rating and set a $1.50 price objective on the stock in a report on Monday, July 17th. ValuEngine lowered shares of VIVUS from a “buy” rating to a “hold” rating in a research report on Friday, September 1st.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/25/vivus-vvus-getting-somewhat-favorable-news-coverage-report-shows.html.

About VIVUS

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

Insider Buying and Selling by Quarter for VIVUS (NASDAQ:VVUS)

Receive News & Stock Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related stocks with our FREE daily email newsletter.